Related Experiment Video
Updated: Sep 17, 2025
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
[Features of care of patients with cardiovascular diseases and cognitive disorders]
S V Litvinova1, A I Kochetkov1, O D Ostroumova1,2
1Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
Insights
Cognitive impairment (CI) is rising with life expectancy, linked to cardiovascular diseases (CVD) like atherosclerosis. Early intervention with drugs such as atorvastatin and nicergoline may help manage CI progression and its impact.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Increasing life expectancy correlates with a higher prevalence of cognitive impairment (CI).
- Cardiovascular diseases (CVD), particularly atherosclerosis, are significant risk factors for developing CI.
- CI negatively impacts functional autonomy, work capacity, and treatment adherence, creating a detrimental cycle.
Purpose of the Study:
- To explore the relationship between cardiovascular health and cognitive function.
- To discuss the role of statins, specifically atorvastatin, in managing cardiovascular disease and potentially mitigating CI.
- To review the therapeutic applications of nicergoline in symptomatic management of CI and related neurological conditions.
Main Methods:
- Literature review on cognitive impairment, cardiovascular diseases, atherosclerosis, statins (atorvastatin), and nicergoline.
- Analysis of the impact of CVD on cognitive decline.
- Examination of pharmacological interventions for CI.
Main Results:
- Atorvastatin is a well-established statin for cardiovascular disease prevention and safety.
- Nicergoline has a long history of use in symptomatic therapy for CI, dementia, and cerebrovascular damage.
- Early CI therapy is crucial as it is a progressive disorder leading to dementia.
Conclusions:
- Cardiovascular health management is critical for preventing cognitive decline.
- Atorvastatin and nicergoline represent potential therapeutic options for managing CI and associated conditions.
- Timely intervention is essential for managing progressive cognitive impairment and its consequences.
Abstract:
Due to the increase in life expectancy of the population, the proportion of people with cognitive impairment (CI) is also increasing. Today, it is known that cardiovascular diseases (CVD) are a significant risk factor for the development of CI. At the same time, the main substrate of CVD, including cerebrovascular events, is atherosclerosis. Statins are one of the most studied classes of drugs in the prevention of CVD. Atorvastatin (Liprimar) is one of the most studied and most frequently prescribed statins that has proven its effectiveness and safety in patients with a wide range of cardiovascular pathology. CI, in turn, lead to a decrease in functional autonomy, ability to work and adherence to treatment, thereby closing the vicious circle. Thus, therapy for CI should be initiated as early as possible, since they are a progressive disorder that eventually transforms into dementia. One of the drugs that has been used for 50 years for symptomatic therapy of CI, including dementia, chronic cerebrovascular and organic brain damage, is nicergoline (Sermion).
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:23Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
01:29Cardiomyopathy VI: Nursing Management
01:23Atherosclerosis IV: Nursing Management
01:29Cardiomyopathy V: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care